Rybelsus (Oral Semaglutide) in the UK: What It Is & Availability

What is Rybelsus?

Rybelsus is oral semaglutide — the same active ingredient as the injectable medicines Ozempic (for type 2 diabetes) and Wegovy (for weight management), but taken as a once-daily tablet instead of a weekly injection. It belongs to the GLP-1 receptor agonist class. It is made by Novo Nordisk and, in the UK, is authorised by the Medicines and Healthcare products Regulatory Agency (MHRA).

Because semaglutide is a large peptide that stomach acid would normally break down, the Rybelsus tablet contains an absorption enhancer to help a small amount cross into the bloodstream. That chemistry is why the tablet has strict rules about how it is taken (see below), and it is why oral semaglutide is a genuinely different product from the newer small-molecule oral GLP-1 pills in development.

Is Rybelsus for diabetes or weight loss?

Type 2 diabetes. The UK licensed (authorised) indication is, in the manufacturer's own wording, for “the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise” — either on its own where metformin is unsuitable, or alongside other diabetes medicines.

Is Rybelsus available in the UK?

Yes. Rybelsus is licensed and available in the UK for type 2 diabetes:

• It can be prescribed on the NHS where a clinician judges it appropriate, within NICE type 2 diabetes guidance (NG28). GLP-1 medicines are usually considered after other treatments, and local Integrated Care Board (ICB) formularies set their own criteria — so availability can vary by area.
• It can be prescribed privately for the same licensed use.
• In England, NHS prescriptions for medicines used to manage diabetes are exempt from prescription charges; prescriptions are already free across the rest of the UK.

Whether Rybelsus is the right choice — versus other tablets or an injectable GLP-1 — is a clinical decision. Bring it up with your GP, practice pharmacist, or diabetes team.

The 2025–2026 reformulation: strengths are changing

This is the most important practical point right now. Novo Nordisk is replacing the original Rybelsus tablets with a new formulation that is absorbed more efficiently. The new tablets are bioequivalent — the NHS advice is that they have “the same efficacy, safety and method of administration” — but because less drug is needed, the numbers printed on the pack are lower:

The new formulation began rolling out from autumn 2025, and NHS North East London’s guidance note says the old formulation was expected to be orderable until at least 31 January 2026, with patients moved across to the equivalent new strength before then. Both versions may sit on pharmacy shelves at the same time during the changeover.

How Rybelsus is taken (why the timing matters)

We don't give a dosing schedule here — that comes from your prescriber — but the administration rules are unusual and worth knowing, because getting them wrong reduces how well the tablet works. According to the product information, Rybelsus should be:

• Taken on an empty stomach, on first waking, after a fast.
• Swallowed whole with only a sip of water (no more than about half a glass).
• Followed by a wait of at least 30 minutes before eating, drinking, or taking any other tablets.

These rules exist because food and other medicines in the stomach reduce how much semaglutide is absorbed. If the routine is hard to keep to, that is worth discussing with your clinician — it may affect whether a tablet or a weekly injection suits you better.

What does the evidence show?

Oral semaglutide's glucose-lowering effect in type 2 diabetes was established in the manufacturer's large PIONEER phase 3 trial programme, which supported its licence. More recently, a dedicated cardiovascular outcomes trial reported reassuring results:

As with all GLP-1 medicines, the most common side effects are gut-related (nausea, vomiting, diarrhoea, abdominal pain), and these are often what leads people to stop or change treatment. These are trial-level and label findings, not a prediction of what any one person will experience — your own risks and benefits should be weighed with your clinician. For a plain-English rundown of semaglutide side effects, see our semaglutide side effects guide.

What UK patients should do

• If you already take Rybelsus: expect the tablet strength printed on your box to change during the switch. Take exactly what your prescriber and pharmacist tell you, and don't combine tablets to reach an old number.
• If you want it for diabetes: ask your GP or diabetes team whether oral semaglutide fits your treatment plan under NICE NG28.
• If your goal is weight loss: Rybelsus isn't the licensed route — ask about Wegovy, Mounjaro, and be aware of trade-offs like muscle loss on GLP-1 medicines.
• Don't buy prescription medicines from unregulated sellers — there is a real risk of fake or wrongly dosed products.

Related reading